GE HealthCare has unveiled a new mammography system with artificial intelligence-powered features that it says are aimed at ...

Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...

The FDA has rejected Applied Therapeutics’ attempt to win approval on the strength of a failed phase 3 trial, triggering a 75% drop in the biotech’s share price. Applied said the complete response ...

Proliferative vitreoretinopathy (PVR) is an eye condition that leads to blindness and can currently only be addressed with ...

Philips is expanding its collaboration with Amazon Web Services, focused on providing a cloud-based imaging diagnostics ...

Neuralink said it has received a green light for a new clinical study to test the feasibility of connecting its ...

Trump previously selected Robert Francis Kennedy Jr. to head up the Department of Health and Human Services—the NIH’s parent ...

Outlook Therapeutics’ eye disease drug has failed to match Roche’s Lucentis in a key trial. The biotech brushed off the ...

PTC Therapeutics may reeling from the failure of its amyotrophic lateral sclerosis (ALS) drug utreloxastat yesterday, but the ...